Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27580214 | 0.86 | ALDH1A1 (0.46) | KDM4EALDH1A1GAAGLAAKR1C2 | |
| SCHEMBL1434196 | 0.85 | ALDH1A1 (0.67) | KDM4EALDH1A1GAAAKR1C2POLB | |
| SCHEMBL7838122 | 0.85 | ALDH1A1 (0.47) | KDM4EALDH1A1GAAGLAAKR1C2 | |
| SCHEMBL28430899 | 0.83 | GAA (0.67) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL31693265 | 0.83 | GAA (0.67) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL6314946 | 0.82 | ALDH1A1 (0.47) | KDM4EALDH1A1GAAAKR1C2LMNA | |
| SCHEMBL7823273 | 0.80 | GAA (0.56) | KDM4EALDH1A1GAAGLAAKR1C2 | |
| SCHEMBL7827626 | 0.80 | GAA (0.53) | KDM4EALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL6316128 | 0.80 | LMNA (0.53) | KDM4EALDH1A1GAAGLAAKR1C2 | |
| SCHEMBL11611422 | 0.78 | KDM4E (0.49) | KDM4EALDH1A1GAAGLAAKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0150505-B1 | 3-INDOLECARBOXAMIDE COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1987-04-01 | — | — | EP | disclosed |
| US-4581355-A | HYPOTENSIVE AGENTS, LIPOXYGENASE INHIBITORS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-04-08 | — | — | US | disclosed |
| EP-0150505-A2 | 3-Indolecarboxamide compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | KDM4E 3859/4885ALDH1A1 672/4885GAA 3980/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | KDM4E 3850/4885ALDH1A1 956/4885GAA 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.